Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137835 | 0.95 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPK1RARB | |
| SCHEMBL12650598 | 0.89 | NAAA (0.66) | NPC1RAB9ASMN1; SMN2MAPK1NAAA | |
| SCHEMBL10099547 | 0.87 | NAAA (0.69) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL10099539 | 0.86 | L3MBTL1 (0.69) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL13688471 | 0.85 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2NAAAL3MBTL1 | |
| SCHEMBL11282161 | 0.84 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL18534318 | 0.84 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL29299580 | 0.84 | SMN1; SMN2 (0.53) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL10099538 | 0.84 | HDAC3 (0.61) | NPC1RAB9ASMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL18085918 | 0.84 | HDAC3 (0.63) | NPC1RAB9ASMN1; SMN2MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | NPC1 1099/4885RAB9A 2106/4885SMN1; SMN2 3286/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | NPC1 1099/4885RAB9A 2106/4885SMN1; SMN2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.